These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 29801915)

  • 1. The impact of very short transition times on switching from Natalizumab to Fingolimod on imaging and clinical effectiveness outcomes in multiple sclerosis.
    Vollmer B; Honce JM; Sillau S; Corboy JR; Vollmer T; Nair K; Alvarez E
    J Neurol Sci; 2018 Jul; 390():89-93. PubMed ID: 29801915
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapy of highly active pediatric multiple sclerosis.
    Huppke P; Huppke B; Ellenberger D; Rostasy K; Hummel H; Stark W; Brück W; Gärtner J
    Mult Scler; 2019 Jan; 25(1):72-80. PubMed ID: 28933245
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rituximab versus natalizumab, fingolimod, and dimethyl fumarate in multiple sclerosis treatment.
    Vollmer BL; Nair K; Sillau S; Corboy JR; Vollmer T; Alvarez E
    Ann Clin Transl Neurol; 2020 Sep; 7(9):1466-1476. PubMed ID: 32767538
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Natalizumab versus fingolimod and dimethyl fumarate in multiple sclerosis treatment.
    Vollmer BL; Nair KV; Sillau S; Corboy JR; Vollmer T; Alvarez E
    Ann Clin Transl Neurol; 2019 Feb; 6(2):252-262. PubMed ID: 30847358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Switching from natalizumab to fingolimod treatment in multiple sclerosis: real life data from the Austrian MS Treatment Registry.
    Guger M; Enzinger C; Leutmezer F; Kraus J; Kalcher S; Kvas E; Berger T;
    J Neurol; 2019 Nov; 266(11):2672-2677. PubMed ID: 31312958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness and baseline factors associated to fingolimod response in a real-world study on multiple sclerosis patients.
    Esposito F; Ferrè L; Clarelli F; Rocca MA; Sferruzza G; Storelli L; Radaelli M; Sangalli F; Moiola L; Colombo B; Martinelli Boneschi F; Comi G; Filippi M; Martinelli V
    J Neurol; 2018 Apr; 265(4):896-905. PubMed ID: 29435643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world effectiveness of natalizumab and fingolimod compared with self-injectable drugs in non-responders and in treatment-naïve patients with multiple sclerosis.
    Prosperini L; Saccà F; Cordioli C; Cortese A; Buttari F; Pontecorvo S; Bianco A; Ruggieri S; Haggiag S; Brescia Morra V; Capra R; Centonze D; Di Battista G; Ferraro E; Francia A; Galgani S; Gasperini C; Millefiorini E; Mirabella M; Pozzilli C
    J Neurol; 2017 Feb; 264(2):284-294. PubMed ID: 27878443
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term neuroprotective effects of natalizumab and fingolimod in multiple sclerosis: Evidence from real-world clinical data.
    Noteboom S; Strijbis EMM; Coerver EME; Colato E; van Kempen ZLE; Jasperse B; Vrenken H; Killestein J; Schoonheim MM; Steenwijk MD
    Mult Scler Relat Disord; 2024 Jul; 87():105670. PubMed ID: 38772150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pulsed corticosteroid treatment in MS patients stabilizes disease activity following natalizumab withdrawal prior to switching to fingolimod.
    Evangelopoulos ME; Koutoulidis V; Andreadou E; Evangelopoulos DS; Kilidireas C
    Int J Neurosci; 2016 Dec; 126(12):1097-102. PubMed ID: 26727713
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Increased disease activity in a case of multiple sclerosis after switching treatment from fingolimod to natalizumab].
    Akatani R; Chihara N; Katanazaka K; Ueda T; Sekiguchi K; Matsumoto R
    Rinsho Shinkeigaku; 2019 Aug; 59(8):536-540. PubMed ID: 31341130
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Switching natalizumab to fingolimod within 6 weeks reduces recurrence of disease activity in MS patients.
    Leurs CE; van Kempen ZL; Dekker I; Balk LJ; Wattjes MP; Rispens T; Uitdehaag BM; Killestein J
    Mult Scler; 2018 Oct; 24(11):1453-1460. PubMed ID: 28823223
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fingolimod reduces recurrence of disease activity after natalizumab withdrawal in multiple sclerosis.
    Havla J; Tackenberg B; Hellwig K; Meinl I; Krumbholz M; Seitz F; Eienbröker C; Gold R; Hohlfeld R; Kleiter I; Kümpfel T
    J Neurol; 2013 May; 260(5):1382-7. PubMed ID: 23266894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Previous treatment influences fingolimod efficacy in relapsing-remitting multiple sclerosis: results from an observational study.
    Baldi E; Guareschi A; Vitetta F; Senesi C; Curti E; Montepietra S; Simone AM; Immovilli P; Caniatti L; Tola MR; Pesci I; Montanari E; Sola P; Granella F; Motti L; Ferraro D
    Curr Med Res Opin; 2014 Sep; 30(9):1849-55. PubMed ID: 24831186
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Shortening the washout to 4 weeks when switching from natalizumab to fingolimod and risk of disease reactivation in multiple sclerosis.
    Naegelin Y; Rasenack M; Andelova M; Von Felten S; Fischer-Barnicol B; Amann M; Mehling M; Kappos L; Sprenger T; Derfuss T
    Mult Scler Relat Disord; 2018 Oct; 25():14-20. PubMed ID: 30014876
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative analysis of first-year fingolimod and natalizumab drug discontinuation among Swedish patients with multiple sclerosis.
    Frisell T; Forsberg L; Nordin N; Kiesel C; Alfredsson L; Askling J; Hillert J; Olsson T; Piehl F
    Mult Scler; 2016 Jan; 22(1):85-93. PubMed ID: 25921036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety of switching from natalizumab straight into fingolimod in a group of JCV-positive patients with multiple sclerosis.
    Fragoso YD; Alves-Leon SV; Becker J; Brooks JB; Correa EC; Damasceno A; Gama PD; Gama RA; Matta AP; Maciel EP; Winckler TC
    Arq Neuropsiquiatr; 2016 Aug; 74(8):650-2. PubMed ID: 27556377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention of rebound effect after natalizumab withdrawal in multiple sclerosis. Study of two high-dose methylprednisolone schedules.
    Fuentes-Rumí L; Hernández-Clares R; Carreón-Guarnizo E; Valero-López G; Iniesta-Martinez F; Cabrera-Maqueda JM; León-Hernández A; Zamarro-Parra J; Morales-Ortiz A; Meca-Lallana JE
    Mult Scler Relat Disord; 2020 Sep; 44():102311. PubMed ID: 32593958
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BEST-MS: A prospective head-to-head comparative study of natalizumab and fingolimod in active relapsing MS.
    Cohen M; Mondot L; Bucciarelli F; Pignolet B; Laplaud DA; Wiertlewski S; Brochet B; Ruet A; Defer G; Derache N; Vermersch P; Zephir H; Debouverie M; Mathey G; Berger E; Cappé C; Labauge P; Carra C; De Seze J; Bigaut K; Brassat D; Lebrun-Frenay C
    Mult Scler; 2021 Sep; 27(10):1556-1563. PubMed ID: 33124504
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relapses and obstetric outcomes in women with multiple sclerosis planning pregnancy.
    Berenguer-Ruiz L; Gimenez-Martinez J; Palazón-Bru A; Sempere AP
    J Neurol; 2019 Oct; 266(10):2512-2517. PubMed ID: 31256279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Healthcare resource use and relapses with fingolimod versus natalizumab for treating multiple sclerosis: a retrospective US claims database analysis.
    Bergvall N; Lahoz R; Reynolds T; Korn JR
    Curr Med Res Opin; 2014 Aug; 30(8):1461-71. PubMed ID: 24754349
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.